When will the patents on COLYTE WITH FLAVOR PACKS expire, and when will COLYTE WITH FLAVOR PACKS go generic?

Sponsor	Phase
Incheon St.Mary's Hospital	Phase 3
Seoul National University Hospital	Phase 3
Inje University	N/A

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strides Pharma Intl	COLYTE WITH FLAVOR PACKS	polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous	FOR SOLUTION;ORAL	018983-012	Oct 8, 1998		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 5, 2026

COLYTE with Flavor Packs is a mature, prescription polyethylene glycol 3350 and electrolyte bowel-preparation product used before colonoscopy and other gastrointestinal procedures. Its commercial position is driven by low-cost generic supply, institutional contracting, pharmacy substitution, and procedure volumes rather than patent exclusivity. Public sources do not disclose product-level revenue, EBITDA, or unit sales. The product has no meaningful remaining regulatory exclusivity and faces competition from generic 4-liter polyethylene glycol solutions and branded lower-volume preparations.

What is COLYTE with Flavor Packs?

COLYTE with Flavor Packs is an oral solution powder containing polyethylene glycol 3350, sodium chloride, sodium bicarbonate, and potassium chloride. The product is supplied as a large-volume powder that is reconstituted with water. Flavor packets are used to improve palatability.

The product is indicated for cleansing the colon before colonoscopy, barium enema examination, or other diagnostic procedures requiring a clean bowel [1].

Attribute	COLYTE with Flavor Packs
Active ingredient	Polyethylene glycol 3350 with electrolytes
Dosage form	Powder for oral solution
Typical reconstituted volume	Approximately 4 liters
Therapeutic category	Gastrointestinal bowel preparation
Primary use	Colorectal procedure preparation
FDA pathway	New Drug Application product with long-established generic competition
Regulatory position	Mature prescription product
Biosimilar relevance	None
Product-level public revenue	Not separately disclosed

COLYTE is an iso-osmotic preparation. The electrolyte composition is designed to reduce net absorption and secretion of water and electrolytes during bowel cleansing [1].

What is the FDA regulatory status of COLYTE?

COLYTE with Flavor Packs was approved under NDA 018996. The product’s original approval dates to the 1980s, placing it well beyond the five-year new-chemical-entity exclusivity period and any potential three-year exclusivity associated with a qualifying supplemental approval [2].

The FDA label identifies polyethylene glycol 3350 and electrolytes as the active components. The product remains subject to prescription-drug labeling, manufacturing, quality, adverse-event, and postmarketing requirements.

Does COLYTE have FDA exclusivity?

No meaningful FDA exclusivity remains. The product’s regulatory protection is based on an old NDA and commercial availability, not current new-drug exclusivity.

The product also does not benefit from orphan-drug exclusivity, pediatric exclusivity, or biologic reference-product exclusivity. Biosimilar competition is not relevant because COLYTE is a chemical drug product, not a biologic.

What is the Orange Book status of COLYTE?

COLYTE is associated with an established FDA NDA and has long faced competing polyethylene glycol electrolyte products. Public Orange Book information does not indicate a commercially significant period of unexpired patent protection that would prevent generic competition for the core bowel-preparation formulation [3].

For this type of mature product, the key Orange Book questions are:

Whether any patent is listed against the specific NDA.
Whether the listed patent has expired.
Whether generic applicants must certify under Paragraph IV.
Whether any formulation, method-of-use, or manufacturing patent remains enforceable.

The commercial market indicates that generic polyethylene glycol electrolyte solutions have been available for many years. That substantially reduces the practical importance of any historical patent listing.

What patents protect COLYTE with Flavor Packs?

The core COLYTE formulation is not protected by a current patent estate comparable to newer specialty pharmaceuticals. The relevant intellectual-property position is primarily historical.

IP category	Current commercial significance
Core polyethylene glycol-electrolyte formulation	Low; long-established technology
Flavor-pack configuration	Low; packaging and palatability feature rather than a durable exclusivity platform
Method-of-use patents	No material exclusivity identified for routine bowel cleansing
Manufacturing patents	Potentially relevant to individual suppliers, but not a market barrier
Device or delivery patents	Not central to the product
Regulatory exclusivity	Expired
Biosimilar protections	Not applicable

What formulations are protected by COLYTE-related patents?

The principal formulation is a 4-liter polyethylene glycol 3350 electrolyte preparation. The formulation’s practical differentiation is its electrolyte balance, powder presentation, flavoring, and established prescribing history. Those characteristics are not sufficient to create meaningful current market exclusivity where therapeutically similar generic products are available.

Manufacturing know-how may still have commercial value. Suppliers must maintain control over powder blending, electrolyte uniformity, moisture control, dissolution behavior, packaging, flavor stability, and finished-product testing. These are operational barriers rather than patent barriers.

When does COLYTE lose exclusivity?

COLYTE lost meaningful exclusivity decades ago. The NDA was approved in the 1980s, and the product has operated in a mature generic market for many years [2].

Milestone	Approximate timing
Original FDA approval	1980s
New-chemical-entity exclusivity	Expired
Historical formulation or method patents	Expired or commercially immaterial
Generic competition	Established
Current market phase	Mature, price-sensitive prescription product

The absence of current exclusivity changes the economic model. Revenue depends on manufacturing cost, wholesaler access, pharmacy coverage, institutional contracts, and the ability to avoid supply interruptions.

Which companies compete with COLYTE?

COLYTE competes in two overlapping segments: high-volume polyethylene glycol-electrolyte solutions and lower-volume branded bowel preparations.

High-volume polyethylene glycol competitors

The closest competitors include:

GoLYTELY and generic polyethylene glycol-electrolyte solutions.
NuLYTELY and related generic products.
TriLyte and other historically marketed 4-liter preparations.
Generic products sold under private-label or distributor labels.

These products are usually interchangeable from a payer and procurement perspective when the prescriber permits substitution.

Lower-volume branded competitors

Lower-volume products compete on tolerability, completion rates, convenience, and patient willingness to complete preparation. The principal branded alternatives include:

SUPREP, a sulfate-based bowel preparation.
Sutab, an oral tablet bowel preparation.
Clenpiq, a low-volume liquid preparation.
MoviPrep, a reduced-volume polyethylene glycol preparation.

Lower-volume products generally carry higher acquisition costs but can obtain demand where physicians and patients place greater value on reduced fluid burden.

Product segment	Volume burden	Price position	Main commercial advantage
COLYTE and generic 4-liter PEG solutions	High	Low	Cost and familiarity
Reduced-volume PEG solutions	Moderate	Medium	Lower fluid burden
SUPREP and similar liquids	Low to moderate	Higher	Convenience and tolerability
SUTAB tablets	Low liquid burden, high tablet burden	Higher	Tablet-based administration

How strong is the COLYTE patent estate?

The patent estate is weak as a source of current exclusivity. COLYTE’s commercial durability comes from market familiarity and manufacturing economics rather than patent protection.

Patent-strength assessment

Factor	Assessment
Remaining composition-of-matter protection	None of practical relevance
Remaining regulatory exclusivity	None
Formulation differentiation	Limited
Generic substitution risk	High
Manufacturing complexity	Moderate
Brand recognition	Established but not strongly protected
Litigation leverage	Low
Ability to sustain premium pricing	Low

A supplier could still defend trade secrets, confidential manufacturing processes, trademarks, and contractual relationships. Those rights do not prevent competing polyethylene glycol products from entering or remaining in the market.

Are there Paragraph IV challenges to COLYTE?

Paragraph IV litigation is not a central current risk for COLYTE. Paragraph IV challenges are most commercially important when an innovator product has an active patent that blocks generic approval or launch. COLYTE is already a mature product with established generic alternatives.

A new applicant seeking approval for a substantially similar polyethylene glycol-electrolyte product could pursue an ANDA and address any listed patents through the applicable certification process. The commercial question would be manufacturing economics and market access, not whether a dominant patent blocks entry.

No material, current Paragraph IV dispute is publicly associated with COLYTE’s core product in the principal FDA and public litigation records reviewed for this analysis.

What patent litigation affects COLYTE?

No major active patent litigation appears to be shaping the COLYTE market. Litigation risk is more likely to arise from:

Product-liability claims involving electrolyte abnormalities or aspiration.
Manufacturing or quality-control disputes.
Trademark and labeling disputes.
Contract disputes with distributors or institutional customers.
Alleged infringement involving a competing lower-volume delivery system.

These risks differ from patent litigation. They can increase costs but are unlikely to restore product exclusivity.

What is the financial trajectory of COLYTE?

Public company filings generally do not report COLYTE revenue as a separate line item. The product’s financial trajectory therefore must be assessed through market structure rather than reported brand sales.

The likely trajectory is mature and price-sensitive:

Volume is supported by recurring colonoscopy and gastrointestinal procedure demand.
Average selling price is constrained by generic substitution and payer pressure.
Revenue is vulnerable to loss of formulary position, contract rebidding, and supply disruptions.
Margin depends on low-cost manufacturing and efficient distribution.
Premium growth is limited because newer products compete through convenience rather than patent-protected clinical superiority.

Revenue exposure

COLYTE is unlikely to be a material standalone revenue driver for a diversified pharmaceutical company unless the product is part of a broader gastrointestinal portfolio. Product-level revenue is more likely to be meaningful for a small generic or specialty supplier with a concentrated product base.

A supplier’s financial exposure can be approximated through four variables:

Variable	Impact on COLYTE economics
Procedure volume	Supports recurring demand
Generic price erosion	Reduces revenue per prescription
Contract concentration	Increases customer loss risk
Manufacturing reliability	Determines ability to retain contracts

The most material upside would come from supply shortages affecting competing products, improved institutional contracting, or portfolio ownership that allows shared manufacturing and distribution. The principal downside would come from further price compression, loss of a major wholesaler relationship, or substitution by lower-volume products.

What licensing deals involve COLYTE?

No material recent licensing transaction centered specifically on COLYTE with Flavor Packs is publicly identified. The product’s age and generic market position make a conventional royalty-bearing licensing model less likely than:

Product acquisition transactions.
In-licensing of broader gastrointestinal portfolios.
Contract manufacturing arrangements.
Private-label supply agreements.
Distributor or group-purchasing contracts.

For mature bowel preparations, commercial value is usually transferred through an asset purchase or supply agreement rather than through a long-term innovation license.

What generic launch risks exist for COLYTE?

Generic launch risk is high in the sense that the product is exposed to ongoing substitution. The more relevant risk is additional generic price competition, not first generic entry.

Generic and supply-chain risks

Additional ANDA approvals can increase rebate and discount pressure.
A low number of qualified manufacturers can create temporary supply shortages.
Raw-material and packaging costs can compress margins.
Institutional buyers can switch suppliers after contract rebidding.
Pharmacy substitution can weaken brand retention.
Flavor and preparation tolerability can shift demand toward lower-volume products.

A 4-liter preparation retains a cost advantage, but patients and physicians may favor products requiring less liquid. This creates a structural tradeoff between procurement economics and patient convenience.

How does COLYTE compare with newer bowel preparations?

COLYTE has the strongest position on cost and the weakest position on convenience.

Factor	COLYTE	Lower-volume branded products
Acquisition cost	Usually lower	Usually higher
Required fluid volume	High	Lower
Generic substitution	High	More limited
Patent protection	Minimal or expired	May remain for some products
Institutional appeal	Strong where cost dominates	Selective
Patient convenience	Weaker	Stronger
Pricing power	Low	Higher when clinically differentiated

COLYTE is more resilient in hospitals, ambulatory surgery centers, Medicaid channels, and cost-controlled formularies. Lower-volume products are better positioned in retail and specialist-prescribing channels where completion, tolerability, and patient preference carry greater weight.

What is the generic launch outlook for COLYTE?

The market does not require a future generic launch to create competitive pressure because generic alternatives are already established. The forward outlook is therefore a replacement and share-retention question.

The most probable commercial scenario is stable-to-declining nominal revenue with recurring baseline demand. Volume can remain durable while price per prescription declines. A stronger outcome would require supply disruption among competitors or a successful contracting strategy. A weaker outcome would involve accelerated substitution by reduced-volume liquids and tablets.

Key Takeaways

COLYTE with Flavor Packs is a mature 4-liter polyethylene glycol-electrolyte bowel preparation.
Its original FDA approval dates to the 1980s, and meaningful regulatory exclusivity has expired.
The core product has no commercially significant current patent barrier identified in public FDA materials.
Generic competition is established, making price, supply reliability, and contracting more important than patent rights.
Biosimilar risk does not apply.
No major active Paragraph IV or patent litigation is shaping the market.
Product-level revenue is not publicly disclosed.
Financial performance is likely stable to declining on a nominal basis, with recurring procedure-driven demand offset by price erosion.
Lower-volume liquids and tablet preparations are the main strategic competitors.
Manufacturing quality, supply continuity, and institutional contracts are the principal commercial defenses.

FAQs

Is COLYTE with Flavor Packs still commercially available?

COLYTE is an established prescription bowel-preparation product, although availability can vary by manufacturer, distributor, pharmacy, and regional supply conditions.

Is COLYTE the same as GoLYTELY?

Both are polyethylene glycol-electrolyte bowel preparations with similar high-volume use, but they are separate branded products and may differ in formulation details, flavoring, packaging, labeling, and supplier.

Can COLYTE be substituted with a generic bowel preparation?

Substitution depends on the prescription, state pharmacy-substitution rules, payer policy, and the pharmacist’s determination that the products are therapeutically interchangeable.

Does COLYTE have a 180-day generic exclusivity period?

A current 180-day first-applicant exclusivity period is not the central market issue for COLYTE because generic polyethylene glycol-electrolyte competition has existed for many years.

Does COLYTE face competition from SUTAB?

Yes. SUTAB competes for the same bowel-preparation indication but uses tablets and a lower liquid burden. Its pricing and prescribing position differ materially from the low-cost, high-volume COLYTE model.

References

DailyMed. (n.d.). COLYTE with flavor packs: Polyethylene glycol 3350, sodium chloride, sodium bicarbonate, and potassium chloride powder for oral solution prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: COLYTE with Flavor Packs, NDA 018996. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.). ANDA approvals and generic drug information. https://www.fda.gov/drugs/generic-drugs
U.S. Food and Drug Administration. (n.d.). SUPREP bowel prep kit, prescribing information. https://www.accessdata.fda.gov/
U.S. Food and Drug Administration. (n.d.). SUTAB prescribing information. https://www.accessdata.fda.gov/

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	6
DailyMed Link:	COLYTE WITH FLAVOR PACKS at DailyMed

COLYTE WITH FLAVOR PACKS Drug Patent Profile

Which patents cover Colyte With Flavor Packs, and when can generic versions of Colyte With Flavor Packs launch?

AI Deep Research

Questions you can ask:

Summary for COLYTE WITH FLAVOR PACKS

Recent Clinical Trials for COLYTE WITH FLAVOR PACKS

US Patents and Regulatory Information for COLYTE WITH FLAVOR PACKS

COLYTE With Flavor Packs Market Dynamics, Patent Status, and Financial Trajectory